Research in LCRC

Fume Exp

LCRC is an internationally renowned research grouping, bringing together basic and clinical scientists and having excellent links with the National Health Service. Our strategic aim is to capitalise on our strong basic scientific research programmes to expand our translational and clinical research to achieve patient benefit.

Key outcomes over the last five years have been:

  • enhanced grant funding, including two successful CR-UK Programme Grants awards;
  • renewal of our ECMC and
  • enhanced funding for mesothelioma and haematology clinical studies.

Research focuses on the following areas:


The overall aim of the Group is to develop and apply strategies for both prevention of cancer. There is an emphasis on the use of biomarkers in mechanistic studies of carcinogenesis and for monitoring the effectiveness of chemoprevention and therapy. Members of this grouping:

Professor Karen Brown
Dr Don JL Jones
Dr Alessandro Rufini
Professor Anne Thomas

Early Detection

Efforts in this area are centred on genomic profiling of circulating free DNA (cfDNA), focussing on the reliable detection of driver mutations in lung, pancreatic, colorectal and breast cancer as well as melanoma. Members of this grouping:

Dr David Guttery
Dr John Le Quesne
Dr Gerald Saldanha

Professor Jacqui Shaw

Personalised Medicine

Research on targeted therapies is primarily coupled to clinical trials of thoracic cancers and lymphoid malignancies with emphasis on overcoming treatment resistance. Members of this grouping:

Professor Martin Dyer
Professor Dean Fennell
Dr David Guttery
Professor Bruno Morgan
Professor Catrin Pritchard
Dr John Le Quesne
Professor Jacqui Shaw
Professor Anne Thomas


Radiation research activity at Leicester is primarily focussed on cancer cell radiosensitivity, specifically focussing on DNA damage measures principally by Comet assay (Jones group), normal tissue radiosensitivity/toxicity focussing on finding the genetic determinants and other biomarkers of adverse reactions to RT (Talbot & Rattay groups) and studies of the long-term effects of radiation exposure,focussing on long-term gene and epigenetic expression changes and transgenerational effects in humans and mice (Dubrova group).

Professor G Don Jones
Dr Tim Rattay
Professor Paul Symonds (Emeritus)
Professor Yuri Dubrova (Department of Genetics and Genome Biology)
Dr Chris Talbot (Department of Genetics and Genome Biology)
Dr Dusan Milanovic (University Hospitals of Leicester NHS Trust)

The conduit for translational and early phase clinical trials is our ECMC, underpinned by a dedicated Early Phase Clinical Trials Unit, funded by a partnership between the NHS Trust, the University and the locally based cancer charity Hope Against Cancer.

We also host the Ernest and Helen Scott Haematological Research Institute and are a leading centre for lung cancer and mesothelioma research.

Our research is funded by a variety of sources including charities Cancer Research UK, Lymphoma Leukaemia Research, Hope Against Cancer as well as a number of commercial organisations.

Hope FoundationLeukemia and Lymphoma ResearchCRUK

Share this page:


Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform


SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper


Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair


Leicester Wellcome Trust Institutional Strategic Support Fund (WTISSF):  

The Leicester WTISSF aims to fund projects that cross discipline, ethnic and social boundaries to promote health. 

The latest award spans over 5 years, from 2016/17 to 2020/21. 

For more information, please click here

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 


AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.